Previous Article | Next Article 
Journal of Clinical Microbiology, May 1998, p. 1220-1225, Vol. 36, No. 5
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Detection of Kanamycin-Resistant
Mycobacterium tuberculosis by Identifying Mutations in the
16S rRNA Gene
Yasuhiko
Suzuki,1,*
Chihiro
Katsukawa,2
Aki
Tamaru,2
Chiyoji
Abe,3
Masanao
Makino,4
Yasuo
Mizuguchi,5 and
Hatsumi
Taniguchi6
Department of
Pathology1 and
Department of
Microbiology,2 Osaka Prefectural Institute of
Public Health, Nakamichi 1-3-69, Higashinari-ku, Osaka 537, The Research Institute of Tuberculosis, Japan
Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo
204,3
National Leprosarium,
Oku-Komyo-en, 6253 Mushiake, Okayama 701-45,4
Public Health Laboratory of Chiba Prefecture, 666-2,
Chuo-ku, Chiba 260,5 and
Department of
Microbiology, School of Medicine, University of Occupational and
Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyusyu
807,6 Japan
Received 2 October 1997/Returned for modification 15 December
1997/Accepted 17 February 1998
 |
ABSTRACT |
In Mycobacterium smegmatis and a limited number of
Mycobacterium tuberculosis strains, the involvement of
alterations of the 16S rRNA gene (rrs) in resistance to
kanamycin has been shown. To investigate the extent to which mutations
in a specific region of the rrs gene and the
kanamycin-resistant phenotype in clinically isolated M. tuberculosis strains were correlated, 43 kanamycin-resistant strains (MICs,
200 µg/ml), 71 kanamycin-susceptible strains, and 4 type strains were examined. The 300-bp DNA fragments carrying the
rrs gene and the intervening sequence between the
rrs gene and 23S rRNA (rrl) gene fragments were
amplified by PCR and were subjected to PCR-based direct sequencing. By
comparing the nucleotide sequences, substitutions were found in 29 of
43 (67.4%) kanamycin-resistant clinical isolates at positions 1400, 1401, and 1483 but in none of the 71 sensitive isolates or the 4 type
strains. The most frequent substitution, from A to G, occurred at
position 1400. A substitution from C to T at position 1401 was found
once. Two clinical isolates carried the double mutation from C to A at
position 1401 and from G to T at position 1483. In addition, we found
that these mutants can be distinguished from wild-type strains by
digestion with the restriction endonucleases TaiI and
Tsp45I. Furthermore, we found that the genotypes of
kanamycin-resistant strains can be discriminated from each other by
digestion with a restriction endonuclease, BstUI or
DdeI.
 |
INTRODUCTION |
Control of tuberculosis caused by
drug-resistant Mycobacterium tuberculosis has become one of
the major problems throughout the world (1, 8). However, the
detection of drug-resistant phenotypes of M. tuberculosis
takes at least 3 and 6 weeks by the direct and indirect methods,
respectively. Thus, treatment is prescribed empirically. Patients who
fail to respond to drugs remain infectious (19). They may be
a source of transmission of infections from patient to patient, from
patients to people who are giving medical treatment (10),
and from a patient to a member(s) of his or her family (17).
Thus, the establishment of a rapid, simple, and reliable method for the
detection of drug-resistant phenotypes of M. tuberculosis is
one of the most urgent needs in the treatment of tuberculosis patients.
Understanding of the molecular basis of resistance might help in the
establishment of a novel method for the detection of drug-resistant
M. tuberculosis strains. This approach has been pursued, and
the detection of drug-resistant M. tuberculosis by genetic
methods has become possible. Nearly 95% of rifampin-resistant strains
can be detected by analyzing a certain part of the RNA polymerase
-subunit gene (21, 25, 27, 29). About 80% of
streptomycin-resistant strains carry mutations on either the rpsL or the rrs gene (12, 15, 21). It
has also been known that resistance to isoniazid is due to mutations in
the catalase-peroxidase gene (katG) (2, 31), the
inhA gene (4), or the aphC
(30) gene. The gene responsible for resistance to ethambutol
has been reported to encode arabinosyltransferases in M. avium (6). The pncA gene encoding
pyrazinamidase-nicotinamidase turned out to be a gene responsible for
pyrazinamide resistance (23). Caceres et al. (7)
reported that the overexpression of the D-alanine racemase
gene confers resistance to D-cycloserine in
Mycobacterium smegmatis. In addition, quinolone-resistant
mutations were found on the gyrA gene, as has been seen in
other bacteria (26). However, a method for the detection of
kanamycin-resistant strains has not yet been established.
Kanamycin is one of the key second-line drugs for the treatment of
tuberculosis. Patients who are suffering from tuberculosis caused by
multidrug-resistant strains with resistance to the first-line antituberculosis drugs such as rifampin, isoniazid, ethambutol, streptomycin, or pyrazinamide have a poor prognosis (15).
For such patients, kanamycin is one of the best choices for treatment.
In bacteria, resistance to kanamycin is attributed to three mechanisms.
One mechanism involves an aminoglycoside-modifying enzyme carried by
transposons (22). The second mechanism is specific
methylation of rRNA. Modification of the rRNA at position 1405 or 1408 was responsible for kanamycin resistance (5). The third
mechanism involves nucleotide changes in the 3' part of the 16S rRNA
gene (rrs) (3, 9). The structural and functional organization of rRNA is highly conserved among bacteria, so it is
reasonable to consider that the same mutation results in resistance to
kanamycin in mycobacteria, as was seen in other bacteria. Recently, we
have used a genetic conjugation system to show that the nucleotide substitution from A to G at position 1389 of the 16S rRNA gene in
M. smegmatis was responsible for the kanamycin-resistant
phenotype. In the same study we showed with a limited number of strains
that there exist some correlations between the mutation from A to G at
position 1400 of the 16S rRNA gene, equivalent to position 1389 of
M. smegmatis, and a kanamycin-resistant phenotype in
M. tuberculosis (28).
To make sure that this observation would be generally applicable for
the identification of clinically isolated M. tuberculosis strains with the kanamycin-resistant phenotype, we have amplified and
sequenced the identical fragment reported previously (28) and compared the results.
In this paper, we discuss the use of sequencing of the rrs
gene segment and PCR product-restriction fragment length polymorphism (PCR-RFLP) analysis as tools for the identification of
kanamycin-resistant M. tuberculosis strains.
 |
MATERIALS AND METHODS |
Bacterial strains.
Kanamycin-susceptible and -resistant
clinical isolates of M. tuberculosis were kindly provided by
the following institutions: Hiroshima University (Hiroshima, Japan),
Osaka Prefectural Habikino Hospital (Osaka, Japan), Research Institute
of Tuberculosis, Japan Anti-Tuberculosis Association (Tokyo, Japan),
National Minami-Fukuoka Hospital (Fukuoka, Japan), National
Fukuoka-higashi Hospital (Fukuoka, Japan), National Sanyoso Hospital
(Yamaguchi, Japan), National Ohmuta Hospital (Fukuoka, Japan), National
Cyubu Hospital (Aichi, Japan), Aihoku Hospital (Aichi, Japan), and
National Sapporo-minami Hospital (Hokkaido, Japan). The type strains
M. tuberculosis H37Rv, H37Ra, Aoyama B, and ATCC 35416 have
been maintained on Ogawa egg medium (Nissui Seiyaku Co., Ltd., Tokyo,
Japan) in our laboratory. Drug susceptibility testing was performed by
the conventional method with Ogawa egg medium. Resistance was generally
defined as survival of the bacilli at the following drug
concentrations: kanamycin, 100 µg/ml; streptomycin, 20 µg/ml;
rifampin, 50 µg/ml; isoniazid, 1 µg/ml; and ethambutol, 5 µg/ml.
The susceptibilities of the strains are as indicated in Table
1.
DNA preparation.
DNAs for PCR were prepared by mechanical
disruption as described previously (25). Briefly, a single
colony on Ogawa medium was picked and suspended in 0.5 ml of lysis
buffer consisting of 0.3 M Tris-HCl (pH 8.0), 0.1 M NaCl, and 6 mM EDTA
in a conical, 2-ml, screw-cap vial, one-fourth of which was filled with
0.17-mm, acid-washed sterile glass beads. Mycobacterial cells were
disrupted by vigorous shaking with 0.5 ml of chloroform on a
Mini-BeadBeater cell disrupter (Biospec Products, Bartlesville, Okla.)
for 5 min. After centrifugation the DNAs in the upper layer were
further purified by phenol-chloroform extraction, concentrated by
ethanol precipitation, and dissolved in 300 µl of TE buffer
consisting of 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA.
PCR procedure.
A pair of primers, TBrrs1250 and TBrrivs38,
was used to amplify a part of the 16S rRNA gene of M. tuberculosis (Fig. 1). Ten nanograms
of DNA was used in a 50-µl PCR mixture consisting of 50 mM Tris-HCl,
50 mM NaCl, 10 mM MgCl2, a 0.2 mM concentration of each
deoxynucleoside triphosphate, a 1 mM concentration of each primer
(TBrrs1250 and TBrrivs38), and 2.5 U of ExTaq DNA polymerase (Takara
Shuzo Co. Ltd., Kyoto, Japan). PCR was performed as follows: 94°C for
10 min, 35 cycles of 30 s at 94°C, 30 s at 55°C, and
60 s at 72°C, followed by 5 min at 72°C for completion. A PCR
thermal cycler (MP; Takara Shuzo) was used throughout.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Strategy and primers used for the PCR amplification and
direct sequencing of the 3' part of the 16S rRNA gene of M. tuberculosis. Two primers, named TBrrs1250 and TBrrivs38, for
amplification of the DNA fragments in which we were interested, were
designed on the basis of the sequence of the rrs gene and
spacer region reported by us (24) and Kempsell et al.
(16). DNA fragments were amplified by using primers
TBrrs1250 and TBrrivs38, and their sequences were determined by using
TBrrs1285F and TBrrivs15F separately.
|
|
PCR-based sequencing of PCR products.
PCR products were
subjected to the purification step by agarose gel electrophoresis. The
block containing the bands in which we were interested was sliced out
of the agarose gel and frozen at
80°C for 10 min, followed by
centrifugation at 15,000 × g for 5 min. The concentration
of DNA fragments in the effluent obtained after the centrifugation was
determined by comparing the density of the band with those of the
HindIII-digested bacteriophage
DNA fragments (Takara
Shuzo) of known concentration. DNA sequences were obtained by a
modified dideoxy procedure by using 0.5 to 1 µg of template per
sequencing reaction with an Autocycle DNA sequencing kit (Pharmacia
Biotech Japan Inc., Tokyo, Japan) or a Sequencing PRO Autosequencer
Core Kit for Labeled Primer (TOYOBO Inc., Osaka, Japan) according to
the manufacturer's procedure. The primers used for the sequencing were
TBrrs1285F and TBrrivs15F (Fig. 1). The reaction mixtures were analyzed
with an A.L.F. fluorescent auto DNA sequencer (Pharmacia Biotech).
Every PCR product from both strands was sequenced.
PCR-RFLP analysis.
The PCR products obtained by using
primers TBrrs1250 and TBrrivs38 were precipitated with 0.1 volume of 3 M sodium acetate and 2 volumes of ethanol, dissolved in TE buffer, and
then digested with the restriction endonucleases TaiI,
Tsp45I, BstUI, and DdeI (New England
Biolabs, Inc., Beverly, Mass.) according to the manufacturer's procedure. Digested PCR products were separated by electrophoresis on a
4% agarose gel (NuSieve GTG agarose; FMC Bioproducts Inc., Rockland,
Maine). The resulting bands were then visualized by staining with SYBR
green nucleic acid gel stain (FMC Bioproducts).
 |
RESULTS |
Nucleotide sequence analysis of 3' part of 16S rRNA gene from
kanamycin-resistant and -susceptible M. tuberculosis.
DNAs
were extracted from a panel of kanamycin-resistant and -susceptible
clinical isolates and type strains of M. tuberculosis. DNA
fragments of 300 bp containing the 3' one-fifth of the 16S rRNA gene
and 38 bp of the intervening sequence between the 16S and the 23S rRNA
genes were made by PCR and were used for PCR-based direct sequencing.
When the chromosomal DNAs of these M. tuberculosis strains
were analyzed by PCR by using the strategy described in Materials and
Methods, the expected products with a length of 300 bp were obtained in
all cases. To reduce artifacts resulting from the misincorporation of
nucleotides by the Taq DNA polymerase and cloning errors,
PCR-based direct sequencing was used. The PCR-amplified DNA fragments
were separated by electrophoresis on 1% agarose gels and were cut out
of the gels as blocks. Template DNA solutions were obtained in the
supernatant after freezing the gel block and centrifuging it at
20,000 × g for 5 min. The nucleotide sequences of the
regions in which we were interested were obtained by the dideoxy method
by using PCR-amplified DNAs as templates. When comparing the nucleotide
sequences with those for the same region reported by us (24)
and Kempsell et al. (16), all 71 clinically isolated
kanamycin-susceptible M. tuberculosis strains and the 4 type
strains (strains H37Rv, H37Ra, Aoyama B, and ATCC 35416) exhibited
identical nucleotide sequences. In striking contrast, three different
mutations were found among the 29 kanamycin-resistant M. tuberculosis strains. An A-to-G nucleotide substitution at position 1400, the most frequent mutation, was observed in 26 of the 43 (60.5%) kanamycin-resistant clinical isolates. The mutant genotype
with a substitution from C to T at position 1401 was found only once
(2.3%). As described above, most of the substitutions were single
nucleotide substitutions. Double nucleotide substitutions (from C to A
at position 1401 and from G to T at position 1483) were found in two
isolates (4.7%). However, no mutations were identified in the specific
region of the rrs genes of 14 kanamycin-resistant isolates
(32.6%) examined in this study (Table
2).
Detection of kanamycin-resistant strains by PCR-RFLP analysis.
The PCR products generated with primers TBrrs1250 and TBrrivs38 were
subjected to digestion with restriction endonuclease TspI,
TaiI, BstUI, or DdeI. As indicated in
Fig. 2A, the PCR products from
kanamycin-susceptible strains carried the Tsp45I recognition sequences (^GTCAC [where the caret represents the cutting
position]; from positions 1397 to 1401) and the TaiI
recognition sequence (ACGT^; from positions 1400 to 1403) at the site
at which most of the mutations were found. The dominant genotype of
kanamycin-resistant clinical isolates contained the novel restriction
site of BstUI (CG^CG; from positions 1399 to 1402) as a
result of conversion of the nucleotide at position 1400 from an A to a
G. The genotype containing a double substitution, from C to A at
position 1401 and from G to T at position 1483, thereby acquired the
restriction recognition sequence of DdeI (C^TAAG; from
positions 1482 to 1486), as shown in Fig. 2B. Thus, the PCR products
obtained from wild-type sequences could be digested with both
Tsp45I and TaiI (Fig.
3A and B, respectively). On the contrary,
BstUI and DdeI digested the PCR product with the
A-to-G mutation at position 1400 and the G-to-T mutation at position
1483 (Fig. 3C and D, respectively). The lengths of the DNA fragments
obtained by digesting the amplicon with these restriction enzymes
exhibited good agreement with the lengths suggested by the nucleotide
sequence when the fragments were analyzed by agarose gel
electrophoresis containing the SYBR green nucleic acid gel stain (Fig.
3).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Expected restriction digestion patterns of amplicons.
The restriction digestion patterns of the DNA fragments in which we
were interested, which were amplified by using primers TBrrs1250 and
TBrrivs38 as described in the legend to Fig. 1, are presented
schematically. (A) Alignment of nucleotide sequences of wild-type (wt)
and mutant alleles from positions 1381 to 1420. The restriction
endonuclease digestion sites of Tsp45I, TaiI, and
BstUI are indicated below the sequences. (B) Alignment of
nucleotide sequences of wild-type and mutant alleles from positions
1464 to 1503. The restriction endonuclease digestion site of
DdeI is indicated below the sequences. (C) PCR-generated
fragments of the wild-type sequence are digested by Tsp45I,
whereas the fragments of strains with mutant alleles are not. (D)
PCR-generated fragments of the wild-type sequence are digested by
TaiI into three fragments, whereas the fragments of strains
with mutant alleles are digested into two fragments. (E) PCR-generated
fragments of the wild-type sequence and mutated sequence at position
1401 are resistant to digestion with BstUI, whereas the
fragments of strains with mutant alleles at position 1400 (from A to G)
are digested into two fragments. (F) PCR-generated fragments of strains
with the mutation at position 1483 (from G to T) are digested into four
fragments, whereas the fragments of other strains are digested into
three fragments.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of the PCR products by PCR-RFLP analysis. The
DNA fragments in which we were interested were amplified by using
primers TBrrs1250 and TBrrivs38, as described in the legend to Fig. 1,
digested with restriction endonucleases, and analyzed by
electrophoresis on a 4% agarose gel. (A) PCR-generated fragments were
digested with Tsp45I. (B) PCR-generated fragments were
digested with TaiI. (C) PCR-generated fragments were
digested with BstUI. (D) PCR-generated fragments were
digested with DdeI. Lane M, DNA marker; lane 1, PCR product
from a kanamycin-susceptible isolate; lane 2, PCR product from a
kanamycin-resistant isolate with the wild-type sequence; lane 3, PCR
product from a kanamycin-resistant isolate with a mutation at position
1401 (C to T); lane 4, PCR product from a kanamycin-resistant isolate
with a mutation at position 1400 (A to G); lane 5, PCR product from a
kanamycin-resistant isolate with mutations at position 1401 (C to A)
and position 1483 (G to T). Numbers on the left indicate the lengths
(in base pairs) of the DNA marker (pUC118 HinfI digests).
|
|
 |
DISCUSSION |
In an earlier study, we showed that kanamycin resistance in
M. smegmatis is due to some alterations in a 30S ribosome
subunit (31). Recently, the precise positions of the
mutations in M. smegmatis were identified by use of the
conjugation system (28) (Fig.
4). The base substitution at position
1389 (from A to G), which is equivalent to position 1400 of M. tuberculosis, was found in the high-level kanamycin-resistant
mutants. Kanamycin-resistant M. smegmatis had other
mutations, from T to A at position 1387 (equivalent to position 1398 of
M. tuberculosis) and from G to T at position 1473 (equivalent to position 1483 of M. tuberculosis). The
mutation at position 1473 in M. smegmatis was characterized as the key mutation for viomycin and capreomycin resistance as well as
kanamycin resistance (28). In Escherichia coli,
mutations at positions 1408, 1409, and 1491 (equivalent to positions
1400, 1401, and 1483 of M. tuberculosis, respectively)
caused resistance to kanamycin, paromomycin, and other aminoglycoside
antibiotics (9, 20).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4.
Locations of mutations in the rrs genes that
cause aminoglycoside resistance in three bacterial species. A portion
including the bases that were reported to be responsible for
aminoglycoside resistance are reproduced from the secondary structure
proposed by Moazed and Noller (20). Arrows indicate the
bases responsible for resistance in E. coli (9),
M. tuberculosis (this study), and M. smegmatis
(28).
|
|
In this study of M. tuberculosis, mutated bases were
observed in the DNAs of 29 strains of kanamycin-resistant clinical
isolates. Twenty-six of 29 strains carried the base substitution from A to G at position 1400 (equivalent to position 1389 of M. smegmatis and position 1408 of E. coli), which appeared
to be responsible for kanamycin resistance. In addition to this
mutation, two clinical isolates possessed the mutation from C to A at
position 1401 (equivalent to position 1390 of M. smegmatis
and position 1409 of E. coli), as well as the mutation from
G to T at position 1483 (equivalent to positions 1473 and 1491 of
M. smegmatis and E. coli, respectively). The
mutation at position 1473 in M. smegmatis was characterized as the key mutation for viomycin, capreomycin, and kanamycin
resistance. In E. coli, an equivalent mutation appeared to
be responsible for resistance to aminoglycoside antibiotics. So, the
mutation at position 1401, together with the mutation at position 1483 in M. tuberculosis found in this study, may be responsible
for kanamycin resistance. Interestingly, nucleotide 1401 is thought to
hydrogen bond with nucleotide 1483. So, the conversion from a C to an A
at position 1401 and a G to a T at position 1484 weakens the strength
of hydrogen bonding (Fig. 3). The same kind of nucleotide substitution
which weakens the strength of hydrogen bonding was found at position
1401 (from C to T). This mutation was not seen in kanamycin-resistant
M. smegmatis but was seen in E. coli. By analogy,
it appears possible that this mutation may be responsible for the
kanamycin resistance in the M. tuberculosis strains that we
studied.
In the kanamycin-resistant M. tuberculosis strains analyzed
in this study, mutations in the rrs gene fragment were found
in 67.4% (29 of 43) of the strains. This percentage is lower than that
for mutations in the specific region of the rpoB gene (more than 95%) in rifampin-resistant M. tuberculosis (21,
25, 27, 29). Similar observations were made for both
streptomycin- and isoniazid-resistant M. tuberculosis
strains. Drug resistance cannot be explained by mutations in one gene
region in these cases. At least three enzymes are involved in
resistance to isoniazid in M. tuberculosis (2, 4, 30,
32), and at least two genes are responsible for streptomycin
resistance (12, 15, 21). So, causes of resistance other than
the mutations in the region studied in this experiment should be
considered. One candidate gene that may be involved in kanamycin
resistance is elongation factor G. Aminoglycoside antibiotics have been
reported to bind to the A site of the 30S ribosome and inhibit
translocation (11, 18). Elongation factor G is known to be
involved in translocation. Fusidic acid-resistant mutants of
Salmonella typhimurium with mutations in elongation factor G
exhibited the kanamycin-resistant phenotype (14).
Considering all of these facts, searching for mutations in the
elongation factor G gene of kanamycin-resistant M. tuberculosis strains may lead to another cause of kanamycin resistance. The existence of genetic elements carrying
aminoglycoside-modifying enzymes such as Tn5 in E. coli (22) have not yet been disproven. Moreover, there
may exist specific methylases that can modify the rRNA at position 1405 or 1408, as described for Streptomyces lividans
(5). In addition, permeability barriers (13) are also candidates for the cause of kanamycin resistance in M. tuberculosis.
Finally, we have tried to develop a rapid and simple method for the
detection of kanamycin-resistant M. tuberculosis by applying PCR-RFLP techniques. The wild-type sequence of the rrs gene
turned out to contain two restriction sites near the position where
mutations associated with kanamycin resistance were found. It was
suggested from the sequence of the amplicon that all PCR-generated DNA
fragments with mutations at either position 1400 or position 1401 were
resistant to Tsp45I, whereas PCR-generated DNA fragments of
the wild-type sequence were digested into two fragments of 175 and 125 bp (Fig. 2A and C). TaiI was supposed to digest the
wild-type amplicon into three fragments with lengths of 171, 98, and 31 bp, whereas the PCR product carrying the mutant sequence will be cut
into only two fragments of 202 and 98 bp (Fig. 2A and D). The mutant allele with the base conversion from A to G at position 1400 has the
BstUI restriction sequence (CG^CG; spanning from positions 1400 to 1403) (Fig. 2A). The PCR-generated DNA fragment with this mutant sequence was guessed to be digested into two fragments with
lengths of 178 and 122 bp, respectively, whereas the PCR-generated DNA
fragment with the wild-type sequence or some other mutant sequence was
guessed to be resistant to this enzyme (Fig. 2E). In addition, the
mutation at position 1483 (from G to T) converts the PCR product into
one that is digestible by the restriction endonuclease DdeI
(recognition sequence, C^TRAG) (Fig. 2B) into four fragments with
lengths of 196, 48, 38, and 14 bp (Fig. 2F). The lengths of the DNA
fragments obtained by restriction digestion exhibited good agreement,
with one exception, with the lengths suggested by the nucleotide
sequence of amplicon when analyzed by agarose gel electrophoresis (Fig.
3); the exception was a 14-bp DdeI fragment which was too
short to be detected with the agarose gel used in this study. All of
the mutant genotypes found in this study can be identified by digesting
the PCR products with at least three restriction endonucleases.
However, the displacement of restriction fragments in TaiI
and DdeI digestion are very small, and much care should be
taken in running the assays and interpreting the results.
It is not clear that the results obtained in this study with clinically
isolated strains only from Japan are applicable to strains from other
countries. For strains resistant to other drugs, such as rifampin and
streptomycin, however, the genes with mutations responsible for
resistance in Japanese isolates were the same as the genes with
mutations responsible for resistance in isolates from other countries
(15, 25, 27). From this finding, the results obtained in
this study may be applicable to strains from all over the world. In
addition, further studies are necessary to answer the question of
whether the results obtained in this study are applicable to
nontuberculous mycobacterial strains.
 |
ACKNOWLEDGMENTS |
We thank N. Hirota, N. Miyazaki, H. Fukunaga, K. Ishibashi, S. Yamori, S. Kawahara, S. Sumi, and all members of the Department of
Clinical Laboratory in Habikino Hospital for gifts of clinical mycobacterial isolates.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Osaka Prefectural Institute of Public Health, Nakamichi
1-3-69, Higashinari-ku, Osaka 537, Japan. Phone: 81-6-972-1321, ext.
268. Fax: 81-6-972-0772. E-mail:
suzuki{at}iph.pref.osaka.jp.
 |
REFERENCES |
| 1.
|
Al-Drainev, I.
1990.
Drug resistance in tuberculosis.
J. Chemother.
2:147-151[Medline].
|
| 2.
|
Altamirano, M.,
J. Marostenmaki,
A. Wong,
M. FitzGerald,
W. A. Black, and J. A. Smith.
1994.
Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates.
J. Infect. Dis.
169:1162-1165[Medline].
|
| 3.
|
Apirion, D., and D. Schlessinger.
1968.
Coresistance to neomycin and kanamycin by mutations in an Escherichia coli locus that affects ribosomes.
J. Bacteriol.
96:768-776[Abstract/Free Full Text].
|
| 4.
|
Banerjee, A.,
E. Dubnau,
A. Quemard,
V. Balasubramanian,
K. Sun Um,
T. Wilson,
D. Collins,
G. de Lisle, and W. R. Jacobs, Jr.
1994.
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
Science
263:227-230[Abstract/Free Full Text].
|
| 5.
|
Beauclerk, A. A. D., and E. Cundliffe.
1987.
Site of action of two ribosomal RNA methylases responsible for resistance to aminoglycoside.
J. Mol. Biol.
193:661-671[Medline].
|
| 6.
|
Belanger, A. E.,
G. S. Besra,
M. E. Ford,
K. Mikusova,
J. T. Belisle,
P. J. Brennan, and J. M. Inamine.
1996.
The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol.
Proc. Natl. Acad. Sci. USA
15:11919-11924.
|
| 7.
|
Caceres, N. E.,
N. B. Harris,
J. F. Wellehan,
Z. Feng,
V. Kapur, and R. G. Barlette.
1997.
Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis.
J. Bacteriol.
179:5046-5055[Abstract/Free Full Text].
|
| 8.
|
Culliton, B.
1992.
Drug-resistant TB may bring epidemic.
Nature
356:473[Medline].
|
| 9.
|
De Stasio, E. A.,
D. Moazed,
H. F. Noller, and A. E. Dahlberg.
1989.
Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions.
EMBO J.
8:1213-1216[Medline].
|
| 10.
|
Dunlap, N. E., and M. E. Kimerling.
1994.
Drug-resistant tuberculosis in adults: implications for the health care worker.
Infect. Agents Dis.
3:245-255[Medline].
|
| 11.
|
Fourmy, D.,
M. I. Recht,
S. C. Blanchard, and J. D. Puglisi.
1996.
Structure of the A site of Escherichia coli 16S ribosomal RNA.
Science
274:1367-1371[Abstract/Free Full Text].
|
| 12.
|
Honore, N., and S. T. Cole.
1994.
Streptomycin resistance in mycobacteria.
Antimicrob. Agents Chemother.
38:238-242[Abstract/Free Full Text].
|
| 13.
|
Hui, J.,
N. Gordon, and R. Kajkioka.
1977.
Permeability barrier to rifampin in mycobacteria.
Antimicrob. Agents Chemother.
11:773-779[Abstract/Free Full Text].
|
| 14.
|
Johanson, U., and D. Hughes.
1994.
Fusidic acid-resistant mutants define three regions in elongation factor G of Salmonella typhimurium.
Gene
143:55-59[Medline].
|
| 15.
|
Katsukawa, C.,
A. Tamaru,
Y. Miyata,
C. Abe,
M. Makino, and Y. Suzuki.
1997.
Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan.
J. Appl. Microbiol.
83:634-640[Medline].
|
| 16.
|
Kempsell, K. E.,
Y. E. Ji,
I. C. E. Estrada,
M. J. Colston, and R. A. Cox.
1992.
The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of Mycobacterium tuberculosis and comparison with Mycobacterium leprae precursor rRNA.
J. Gen. Microbiol.
138:1717-1727.
|
| 17.
|
Kritski, A. L.,
M. J. O. Marques,
M. F. Rabahi,
M. A. M. S. Vieira,
E. Werneck-Barroso,
C. E. S. Carvalho,
G. D. N. Angrade,
R. Bravo-De-Souza,
L. M. Andrade,
P. P. Gontijo, and L. W. Riley.
1996.
Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.
Am. J. Respir. Crit. Care Med.
153:331-335[Abstract].
|
| 18.
|
Misumi, M., and N. Tanaka.
1980.
Mechanism of inhibition of translocation by kanamycin and viomycin: a comparative study with fusidic acid.
Biochem. Biophys. Res. Commun.
92:647-654[Medline].
|
| 19.
|
Mitchison, D., and A. Nunn.
1986.
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Am. Rev. Respir. Dis.
133:423-430[Medline].
|
| 20.
|
Moazed, D., and H. F. Noller.
1987.
Interaction of antibiotics with functional sites in 16S ribosomal RNA.
Nature
327:389-394[Medline].
|
| 21.
|
Morris, S.,
G. H. Bai,
P. Suffys,
L. Portillo-Gomez,
M. Fairchok, and D. Rouse.
1995.
Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis.
J. Infect. Dis.
171:954-960[Medline].
|
| 22.
|
Rothstein, S. J.,
R. A. Jorgensen,
J. C. Yin,
Z. Yongdi,
R. C. Johnson, and W. S. Reznikoff.
1981.
Genetic organization of Tn5.
Cold Spring Harbor Symp. Quant. Biol.
451:99-105.
|
| 23.
|
Scorpio, A., and Y. Zhang.
1996.
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.
Nature Med.
2:662-667[Medline].
|
| 24.
|
Suzuki, Y.,
A. Nagata,
Y. Ono, and T. Yamada.
1988.
Complete nucleotide sequence of the 16S rRNA gene of Mycobacterium bovis BCG.
J. Bacteriol.
170:2886-2889[Abstract/Free Full Text].
|
| 25.
|
Suzuki, Y.,
C. Katsukawa,
K. Inoue,
Y. P. Yin,
H. Tasaka,
N. Ueba, and M. Makino.
1995.
Mutations in rpoB gene of rifampicin resistant clinical isolates of Mycobacterium tuberculosis in Japan.
J. Jpn. Assoc. Infect. Dis.
69:413-419.
|
| 26.
|
Takiff, H. E.,
L. Salazar,
C. Guerrero,
W. Philipp,
W. M. Huang,
B. Kreiswirth,
S. T. Cole,
W. R. Jacobs, Jr., and A. Telenti.
1994.
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone-resistant mutations.
Antimicrob. Agents Chemother.
38:773-780[Abstract/Free Full Text].
|
| 27.
|
Taniguchi, H.,
H. Aramaki,
Y. Nikaido,
Y. Mizuguchi,
M. Nakamura,
T. Koga, and S. Yoshida.
1996.
Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis.
FEMS Microbiol. Lett.
144:103-108[Medline].
|
| 28.
|
Taniguchi, H.,
B. Chang,
C. Abe,
Y. Nikaido,
Y. Mizuguchi, and S. Yoshida.
1997.
Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
J. Bacteriol
179:4795-4801[Abstract/Free Full Text].
|
| 29.
|
Telenti, A.,
P. Imboden,
F. Marchesi,
D. Lowrie,
S. T. Cole,
M. J. Colston,
L. Matter,
K. Schopfer, and T. Bodmer.
1993.
Detection of rifampicin-resistance mutants in Mycobacterium tuberculosis.
Lancet
341:647-650[Medline].
|
| 30.
|
Wilson, T. M., and D. M. Collins.
1996.
ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex.
Mol. Microbiol.
19:1025-1034[Medline].
|
| 31.
|
Yamada, T.,
K. Masuda,
Y. Mizuguchi, and K. Suga.
1976.
Altered ribosomes in antibiotic-resistant mutants of Mycobacterium smegmatis.
Antimicrob. Agents Chemother.
9:817-823[Abstract/Free Full Text].
|
| 32.
|
Zhang, Y.,
B. Heym,
B. Allen,
D. Young, and S. T. Cole.
1992.
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.
Nature
358:591-593[Medline].
|
Journal of Clinical Microbiology, May 1998, p. 1220-1225, Vol. 36, No. 5
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sekiguchi, J.-i., Miyoshi-Akiyama, T., Augustynowicz-Kopec, E., Zwolska, Z., Kirikae, F., Toyota, E., Kobayashi, I., Morita, K., Kudo, K., Kato, S., Kuratsuji, T., Mori, T., Kirikae, T.
(2007). Detection of Multidrug Resistance in Mycobacterium tuberculosis. J. Clin. Microbiol.
45: 179-192
[Abstract]
[Full Text]
-
Criswell, D., Tobiason, V. L., Lodmell, J. S., Samuels, D. S.
(2006). Mutations Conferring Aminoglycoside and Spectinomycin Resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother.
50: 445-452
[Abstract]
[Full Text]
-
Maus, C. E., Plikaytis, B. B., Shinnick, T. M.
(2005). Molecular Analysis of Cross-Resistance to Capreomycin, Kanamycin, Amikacin, and Viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
49: 3192-3197
[Abstract]
[Full Text]
-
Gregory, S. T., Carr, J. F., Dahlberg, A. E.
(2005). A Mutation in the Decoding Center of Thermus thermophilus 16S rRNA Suggests a Novel Mechanism of Streptomycin Resistance. J. Bacteriol.
187: 2200-2202
[Abstract]
[Full Text]
-
Maus, C. E., Plikaytis, B. B., Shinnick, T. M.
(2005). Mutation of tlyA Confers Capreomycin Resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
49: 571-577
[Abstract]
[Full Text]
-
Kruuner, A., Jureen, P., Levina, K., Ghebremichael, S., Hoffner, S.
(2003). Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
47: 2971-2973
[Abstract]
[Full Text]
-
Suzuki, Y., Suzuki, A., Tamaru, A., Katsukawa, C., Oda, H.
(2002). Rapid Detection of Pyrazinamide-Resistant Mycobacterium tuberculosis by a PCR-Based In Vitro System. J. Clin. Microbiol.
40: 501-507
[Abstract]
[Full Text]
-
Bastian, I., Rigouts, L., Palomino, J. C., Portaels, F.
(2001). Kanamycin Susceptibility Testing of Mycobacterium tuberculosis Using Mycobacterium Growth Indicator Tube and a Colorimetric Method. Antimicrob. Agents Chemother.
45: 1934-1936
[Abstract]
[Full Text]
-
Hirano, K., Abe, C., Takahashi, M.
(1999). Mutations in the rpoB Gene of Rifampin-Resistant Mycobacterium tuberculosis Strains Isolated Mostly in Asian Countries and Their Rapid Detection by Line Probe Assay. J. Clin. Microbiol.
37: 2663-2666
[Abstract]
[Full Text]